An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510773-20-00

Acronym

KAR-013

Enrollment

Registered

2024-08-06

Start date

2023-06-12

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Incidence of treatment-emergent adverse events (TEAEs)

Detailed description

Incidence of serious TEAEs, Incidence of TEAEs leading to discontinuation of study drug

Interventions

DRUGKarXT

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of treatment-emergent adverse events (TEAEs)	—

Secondary

Measure	Time frame
Incidence of serious TEAEs, Incidence of TEAEs leading to discontinuation of study drug	—

Countries

Bulgaria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026